News | September 17, 2019

Edgewise Therapeutics Closes $50 Million Series B Financing – Financing to Support Advancing Company’s Lead Product Candidate for Muscular Dystrophy- Boulder, Colo., (September 17, 2019) – Edgewise Therapeutics, a preclinical company developing small molecule...